Elevance raised its 2026 adjusted EPS outlook and set a higher earnings baseline, while projecting at least 12% EPS growth in 2027. Shares fell 1.4%, a broadly flat reaction that tempers the upbeat outlook; the transcript does not identify a specific source of investor disappointment.
Elevance Health’s stock fell 12.6% as investors reacted negatively to cautious commentary on Medicaid margin pressures and the ongoing strategic exits from underperforming Medicaid markets, signaling concerns about margin compression and deceleration in this key segment despite raised EPS guidance.
Elevance Health delivered a strong first quarter, exceeding expectations through solid business performance, strategic realignment, and advanced AI integration, prompting a raised full-year EPS guidance of at least $26.75.